Provided by Tiger Fintech (Singapore) Pte. Ltd.

SILO PHARMA INC.

0.6105
+0.00981.63%
Post-market: 0.5990-0.0115-1.88%16:31 EDT
Volume:151.66K
Turnover:94.00K
Market Cap:5.74M
PE:-0.61
High:0.6453
Open:0.6324
Low:0.6030
Close:0.6007
52wk High:3.37
52wk Low:0.4101
Shares:9.40M
Float Shares:8.72M
Volume Ratio:0.74
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0002
EPS(LYR):-1.1936
ROE:-90.03%
ROA:-43.96%
PB:1.17
PE(LYR):-0.51

Loading ...

Silo Pharma Inc. Announces Date for 2025 Annual Shareholders Meeting

Reuters
·
36 mins ago

BRIEF-Silo Pharma Secures Australian Patent Covering Licensed Ptsd Drug Candidate Expanding Global Ip Portfolio

Reuters
·
Sep 03

Silo Pharma Inc. Announces Date for 2025 Annual Meeting of Shareholders

Reuters
·
Aug 26

Silo Pharma’s Ptsd Candidate Spc-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(B)(2) Pathway

THOMSON REUTERS
·
Aug 19

Silo Pharma Inc - Spc-15 Intranasal Spray Shows Safety With No Toxicities

THOMSON REUTERS
·
Aug 19

Silo Pharma Second Quarter 2025 Earnings: US$0.19 loss per share (vs US$0.30 loss in 2Q 2024)

Simply Wall St.
·
Aug 15

Silo Pharma appoints Corwin Yu to launch crypto treasury platform

TIPRANKS
·
Aug 05

Silo Pharma Inc. Issues 750,000 Shares for Asset Acquisition from MAVS Holdings LLC

Reuters
·
Jul 30

Silo Pharma Inc. Completes Dosing in Safety Study of PTSD Drug SPC-15, Awaits Bioanalytical Results

Reuters
·
Jul 16

Silo Pharma expects preclinical study data on SPC-15 in Q3

TIPRANKS
·
Jul 07

Silo Pharma Inc. Awaits Pre-Clinical Data for SPC-15, Plans IND Submission for PTSD Drug in 2025 with Potential Phase 1 Trials by 2026

Reuters
·
Jul 07

Silo Pharma Inc. Faces Nasdaq Non-Compliance Over Minimum Bid Price Rule

Reuters
·
Jul 04

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

MT Newswires Live
·
Jun 25

Silo Pharma enters into letter of intent to form 50:50 joint venture with Hoth

TIPRANKS
·
Jun 25

BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics

Reuters
·
Jun 25

Silo Pharma Inc. Announces USPTO Notice of Allowance for Biomarker Patent on Novel PTSD Therapeutic SPC-15

Reuters
·
Jun 11

Silo Pharma Inc. Board Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset for Long-Term Value Optimization

Reuters
·
Jun 05

Eric Weisblum, CEO of Silo Pharma Inc., Reports Acquisition of Common Shares

Reuters
·
May 29

Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15

MT Newswires Live
·
May 21

Silo Pharma, Resyca partner for intranasal drug-device study of SPC-15

TIPRANKS
·
May 21